Education
About Us
Working with TipRanks
Follow Us
CryoPort Inc (CYRX)
NASDAQ:CYRX
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.28Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and clear growth drivers: revenue exceeded guidance, commercial cell and gene therapy and BioStorage/BioServices posted robust double-digit gains, the clinical pipeline is deep (86 Phase III, 361 Phase II) and product innovation continues. Management improved adjusted EBITDA by $12M and expects positive adjusted EBITDA in H2 2026, while setting 2026 revenue guidance of $190M–$194M. Offsetting risks are modest near-term headwinds: slower quarterly product growth, short-term costs from expedited site buildouts, gradual realization of DHL partnership benefits, and macro/regulatory uncertainties. Overall, highlights substantially outweigh the manageable lowlights, supporting an optimistic near- to mid-term outlook.Company Guidance
Full-Year Revenue Above Guidance
Revenue from continuing operations of $176.2 million for fiscal 2025, exceeding the high end of prior guidance.
Strong Commercial Cell & Gene Therapy Growth
Commercial cell and gene therapy revenue increased 29% year-over-year to a record $33.4 million and represented ~20% of total revenue for 2025.
Clinical Trial Revenue Expansion
Clinical trial revenue grew 14% year-over-year to $47.1 million; supported a record 760 clinical trials (net increase of 59) and 20 commercial therapies worldwide.
Life Sciences Services Momentum
Life Sciences Services revenue grew 18% year-over-year in 2025, with BioStorage/BioServices up 22%, reflecting expanded scale and higher revenue per client.
Profitability Progress and Margin Improvement
Gross margin improved to 47% and adjusted EBITDA improved by $12 million year-over-year; company expects to achieve positive adjusted EBITDA in the second half of 2026.
Product Innovation and MVE Releases
Life Sciences Products (MVE) revenue grew 7% year-over-year; launched integrated condition monitoring with Cryoverse and the Fusion 800 Series self-sustaining cryogenic freezer, expanding addressable markets.
Strategic Partnerships and Capital Infusion
Completed strategic partnership and sale of CRYOPDP to DHL in 2Q25 (providing substantial capital infusion) and added partnerships with Cardinal Health and Parexel to broaden the ecosystem.
Robust Clinical-to-Commercial Pipeline and 2026 Guidance
Company is 'spring-loaded' with 86 Phase III and 361 Phase II clinical trials, anticipates ~13 BLA/MAA filings (2 already filed), 9 new approvals and 2 label/geographic expansions; 2026 revenue guidance of $190M–$194M (midpoint implying ~8.9% growth over 2025).
CYRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $8.49 | $8.74 | +2.94% |
Nov 04, 2025 | $9.22 | $8.53 | -7.48% |
Aug 05, 2025 | $6.74 | $8.75 | +29.82% |
May 07, 2025 | $5.66 | $6.98 | +23.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CryoPort Inc (CYRX) report earnings?
CryoPort Inc (CYRX) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is CryoPort Inc (CYRX) earnings time?
CryoPort Inc (CYRX) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYRX EPS forecast?
CYRX EPS forecast for the fiscal quarter 2026 (Q1) is -0.22.